Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 patients with cancer: enrichment in familial BRCA1/BRCA2 mutation-negative breast cancer but not in other malignancies
暂无分享,去创建一个
J. Kere | L. Aaltonen | P. Møller | J. Schleutker | Å. Borg | B. Agnarsson | R. Barkardottir | A. Kallioniemi | R. Winqvist | K. Pylkäs | M. Grip | T. Ikonen | K. Syrjäkoski | G. Johannesdottir | A. Arason | A. Gerdes | M. Thomassen | T. Kruse | S. Karppinen | L A Aaltonen | G Johannesdottir | B A Agnarsson | R B Barkardottir | S-M Karppinen | K Backenhorn | T Sydenham | K Syrjäkoski | J Schleutker | T Ikonen | K Pylkäs | K Rapakko | H Erkko | A-M Gerdes | M Thomassen | M Grip | A Kallioniemi | J Kere | A Arason | P Møller | T A Kruse | A Borg | R Winqvist | T. Sydenham | K. Rapakko | H. Erkko | Å. Borg | M. Thomassen | K. Backenhorn | K. Syrjäkoski | Anne-Marie Gerdes | Mervi Grip | Katja Backenhorn
[1] J. Klijn,et al. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. , 2003, Cancer research.
[2] W. Thompson,et al. The genetic attributable risk of breast and ovarian cancer , 1996, Cancer.
[3] Karl-Heinz Krause,et al. BARD1 induces apoptosis by catalysing phosphorylation of p53 by DNA-damage response kinase , 2005, Oncogene.
[4] E. Sensi,et al. Germline mutations of the BRCA1‐associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations , 2002, Genes, chromosomes & cancer.
[5] Nazneen Rahman,et al. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002, Nature Genetics.
[6] M. Monden,et al. Mutational analysis of BARD1 in familial breast cancer patients in Japan. , 2003, Cancer letters.
[7] A. Syvänen. Solid-phase minisequencing as a tool to detect DNA polymorphism. , 1998, Methods in molecular biology.
[8] M. Sauer,et al. Identification and characterization of missense alterations in the BRCA1 associated RING domain (BARD1) gene in breast and ovarian cancer , 2005, Journal of Medical Genetics.
[9] Ralph Scully,et al. Dynamic Changes of BRCA1 Subnuclear Location and Phosphorylation State Are Initiated by DNA Damage , 1997, Cell.
[10] D. Easton,et al. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. , 1995, American journal of human genetics.
[11] J Chang-Claude,et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.
[12] B. Trask,et al. Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers. , 1998, Human molecular genetics.
[13] D. Bentley,et al. Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.
[14] A. Olshen,et al. BARD1 Participates with BRCA1 in Homology-Directed Repair of Chromosome Breaks , 2003, Molecular and Cellular Biology.
[15] R. Winqvist,et al. Mutation screening of the BARD1 gene: evidence for involvement of the Cys557Ser allele in hereditary susceptibility to breast cancer , 2004, Journal of Medical Genetics.
[16] L. Ala‐Kokko,et al. Conformation sensitive gel electrophoresis for simple and accurate detection of mutations: comparison with denaturing gradient gel electrophoresis and nucleotide sequencing. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[17] Anne M. Bowcock,et al. Identification of a RING protein that can interact in vivo with the BRCA1 gene product , 1996, Nature Genetics.
[18] J. Manley,et al. The BARD1-CstF-50 Interaction Links mRNA 3′ End Formation to DNA Damage and Tumor Suppression , 2001, Cell.
[19] H. Kovar,et al. Interaction of the EWS NH2 terminus with BARD1 links the Ewing's sarcoma gene to a common tumor suppressor pathway. , 2002, Cancer research.
[20] T. Ohta,et al. The RING Heterodimer BRCA1-BARD1 Is a Ubiquitin Ligase Inactivated by a Breast Cancer-derived Mutation* , 2001, The Journal of Biological Chemistry.
[21] Heli Nevanlinna,et al. BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition , 2006, European Journal of Human Genetics.
[22] Steven E. Bayer,et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.
[23] Stefan Schüchner,et al. Nuclear Targeting and Cell Cycle Regulatory Function of Human BARD1* , 2005, Journal of Biological Chemistry.
[24] C. Jefford,et al. Identification of BARD1 as mediator between proapoptotic stress and p53-dependent apoptosis. , 2001, Molecular cell.
[25] Douglas F. Easton,et al. Polygenic susceptibility to breast cancer and implications for prevention , 2002, Nature Genetics.
[26] A. Bowcock,et al. Cell cycle-dependent colocalization of BARD1 and BRCA1 proteins in discrete nuclear domains. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[27] R. Wooster,et al. Breast and ovarian cancer. , 2003, The New England journal of medicine.
[28] C. Scheidereit,et al. The Bcl-3 oncoprotein acts as a bridging factor between NF-κB/Rel and nuclear co-regulators , 1999, Oncogene.
[29] M. King,et al. BRCA1 RING Domain Cancer-predisposing Mutations , 2001, The Journal of Biological Chemistry.
[30] J. Manley,et al. Functional interaction of BRCA1-associated BARD1 with polyadenylation factor CstF-50. , 1999, Science.
[31] Julian Peto,et al. Identification of the breast cancer susceptibility gene BRCA2 , 1996, Nature.
[32] C. Jefford,et al. Nuclear–cytoplasmic translocation of BARD1 is linked to its apoptotic activity , 2004, Oncogene.
[33] N E Day,et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes , 2002, British Journal of Cancer.